LLY Eli Lilly and Company
Eli Lilly and Company (LLY) trend channel, buy level and 3-month target on Trade The Path. Sector: Healthcare. Listed on NYSE. Levels below are fitted to this ticker's own swing highs and lows (Theil–Sen, log-price), then projected 3 months. On this symbol, 6 comparable calls have settled; 83.3% reached the published sell target. Information only, not financial advice.
Mid-channel, rising on both timeframes
Price is between the two trend lines. Nothing to act on yet.
Read from the last 12 months of history we hold: rising, drifting +34% a year. The target of US$1,327 sits above the nearest ceiling (US$1,299), so reaching it means breaking a line this stock has repeatedly turned at. What would overturn this: a close below US$745.27 — the floor of the channel being read — after which the trend, not the entry, is what was wrong.
- 12 months read from
- US$744.73 – US$1,299 Rising channel, +34% a year
- Position in that channel
- 71% 0% at the floor, 100% at the ceiling
Price history, with the path projected 3 months forward
- Daily close
- Upper trend line (12 months)
- Lower trend line (12 months)
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy now
US$1,138
last close · 16 Sept 2026
Channel buy is US$1,154; last close is the better price available now.
Our target
US$1,327
by 3 Dec 2026
Projected move
16.5%
gross, before costs
Last close is our buy — the best price available now.
The lines are drawn where this stock has actually turned: 4 touches on the ceiling, 3 on the floor, each fitted to the slope that catches the most of them. Buying one average daily range below its 50-day mean, on heavier volume than usual and while it is still above its 200-day mean, has come up 791 times; measured against the 6% floor — the least a call has to be worth to be worth making, not what it aims at — 73% cleared it, typically in 34 days, with price going about 5% against the entry along the way (63% in the worst case we have on record). Trades that have not reached the target within 3 months are counted as misses, whatever they are worth at the time. The prices above are this stock’s own — its average, its volatility — but the setup is the same one we apply everywhere: derived on eight unrelated tickers, then confirmed on 87 others it was never fitted to. We deliberately do not tune it to each stock: doing so scores worse on history the tuning never saw — 58% against 71% — because it fits the past rather than the future. On this stock the setup has come up 10 times so far, reaching target 90% of the time. The sell price comes from where this stock is projected to be, not from a minimum worth taking: the fitted path reaches 15% above the entry within 90 days, and of the sizes that path supports, 15% is the one that has returned the most per day of money tied up here — measured over the 11 times this entry has come up on this chart, reached 91% of the time, typically in 47 days. Smaller sizes got there sooner but paid less for the weeks they used; larger ones need a break above the projected ceiling, which is not the base case. The date published is whichever is later: that typical time, or the day the projected path itself reaches the price. It is a prediction, so it can be revised: if the run tops out before it gets there, the target is cut to what is actually on the table and you are told the same day. An ordinary pullback is not treated as topping out — those go on to make a new high about 8 times in 10, so they are ridden through. What triggers the revision is price closing below its 50-day trend and staying there, after which the odds of recovery fall to roughly 3 in 10.
On this stock's own history these rules produced 6 settled calls, of which 5 reached target (83.3%), with an average best move of 11%. See the full record.
- Upper line touches
- 4
- Lower line touches
- 3
- Fit confidence
- 75%
- Fitted
- 16 Sept 2026
About Eli Lilly and Company
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- David A. Ricks
- Employees
- 50,000
- Country
- US
Scorecard
Our own pillar scores, computed from the fundamentals below. They are not Morningstar ratings — that data is licensed and we do not redistribute it.
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$1.06T
- Enterprise value
- —
- Beta
- 0.50
- Avg volume
- 3.02M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 712.05-1292.65
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted statistically to past swing highs and lows and projected forward on the assumption the same rhythm continues. It often does not. This is information, not advice.